2025 holds a significant opportunity for Outlook Therapeutics Inc. (OTLK), as it prepares for the first commercial launch of LYTENAVA, the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union and United Kingdom.
Roche's Bevacizumab, sold under the brand name Avastin among others, is a drug used to treat various forms of cancer. It is also used off-label to treat eye diseases like wet age-related macular degeneration. Since there are no approved ophthalmic formulations of Bevacizumab, clinicians wishing to treat retinal patients with Bevacizumab have to use unapproved repackaged IV Bevacizumab provided by compounding pharmacies. This approach carries risks of contamination and inconsistent potency and availability.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.